Mainz Biomed NV (NASDAQ: MYNZ), a molecular genetics diagnostic company focused on early cancer detection, announced that Nasdaq confirmed its regained compliance with the minimum stockholders’ equity requirement (Listing Rule 5550(b)(1)) on January 23, 2025. The company had previously achieved compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). Mainz Biomed now fully meets all Nasdaq listing requirements and will remain listed and traded on the Nasdaq Capital Market.

Please follow us to stay up to date:

About Mainz Biomed NV
Mainz Biomed develops molecular genetic diagnostic tools for serious illnesses. Its primary product, ColoAlert®, is a non-invasive colorectal cancer early detection test marketed in Europe and the UAE. A pivotal FDA clinical trial is underway for US approval. The company is also developing PancAlert, a pancreatic cancer screening test. For more information, please visit or follow us on , and .

For media inquiries
MC Services AG
Anne Hennecke/ Simone Neeten
+49 211 529252 20

For investor inquiries, please contact

Forward-Looking Statements
This press release includes forward-looking statements, subject to risks and uncertainties under the Private Securities Litigation Reform Act of 1995. These statements, often using words like “anticipate,” “believe,” and “expect,” are based on current information and are not guarantees of future results. Actual results could differ materially due to factors including, but not limited to, failure to meet development targets, regulatory changes, the impact of the COVID-19 pandemic, and other risks detailed in the company’s SEC filings (including its Form 20-F filed April 9, 2024) available at www.sec.gov. Any forward-looking statement speaks only as of its date, and Mainz Biomed assumes no obligation to update it.

“`